Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

The NAMPT inhibitors market is projected to grow at an annualized rate of 15.08% during the period 2029-2040, claims Roots Analysis London, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “NAMPT Inhibitors Market, 2022-2040” report to its list of offerings Cancer is one of the leading causes of...